Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Philip Morris International Inc. (PM) Price & Performance

Inovio Pharmaceuticals IncTrade
Philip Morris International Inc.Trade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Philip Morris International Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $76.09M), while Philip Morris International Inc. trades at $186.22 (market cap $289.90B). The key difference: Philip Morris International Inc. is far larger — about 3810× Inovio Pharmaceuticals Inc's market cap, and Philip Morris International Inc. pays a 3.16% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

INOPM
Market Cap
$76.09M$289.90B
Sector
HealthConsumer Staples
52-Week High
$2.87$200.17
52-Week Low
$0.66$144.33
Enterprise Value
$47.10M$333.02B
Dividend Yield
3.16%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO trades at $0.668, down 0.86% with bearish technical signals despite recent earnings beats. The company shows minimal revenue of $65,340 against substantial losses, with negative margins and cash flow challenges. Key catalyst is the FDA's October 2026 decision on INO-3107, while recent $20 million offering aims to fund operations.

High-risk biotech play with binary FDA outcome driving valuation. Analyst consensus is bullish (53% buy) with $3.25 price target, but fundamental weaknesses and litigation risks require caution. Success of INO-3107 is critical for turnaround, with current cash funding operations into early 2027.

Philip Morris International Inc.

Philip Morris International (PM) trades at $186.22, down 1.77% with mixed technical signals. The company reported strong Q1 and Q2 2026 earnings beats but faces margin pressure from rising costs. Revenue grew to $40.65B in 2025 with a robust 25.56% net income margin. Analyst consensus remains bullish with a $211.17 price target, though recent news highlights challenges including a $500M impairment charge and increased illicit cigarette trade in Europe.

PM offers solid fundamentals with high profitability and dividend yield, but near-term headwinds from cost inflation and regulatory risks warrant caution. The stock's valuation at 25.54x P/E is reasonable given earnings growth potential, making it attractive for long-term investors despite current volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO

About Philip Morris International Inc.

Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.

Read more on PM